Señales en vivo de CRBP | Maximiza tus Ganancias con Getagraph.com

VENDER 107941 min ago

@ $23.69

Emitido: 14 feb 2024 @ 09:41

Retorno: 47.70%

Señal anterior: feb 13 - 09:30

Señal anterior: Comprar

Retorno: 11.15 %

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 09:42):

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...

Stats
Volumen de hoy	2 239.00
Volumen promedio	404 033
Capitalización de mercado	367.15M
EPS	$0 ( 2024-03-12 )
Próxima fecha de ganancias	( $-1.090 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.39
ATR14	$0.105 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Moran Sean F.	Buy	1 787	Common Stock
2024-04-10	Moran Sean F.	Sell	1 787	Employee Stock Option (right to buy)
2024-03-08	Cormorant Asset Management, Lp	Buy	8 862	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	156 597	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	61 668	Common Stock

INSIDER POWER
99.57
Last 95 transactions
Buy: 14 080 389 \| Sell: 365 661

Volumen Correlación

Largo: -0.13 (neutral)

Corto: -0.78 (moderate negative)

Signal:(65.929) Neutral

Corbus Pharmaceuticals Correlación

10 Correlaciones Más Positivas
VKTX	0.923
BLPH	0.919
CHMA	0.904
BTF	0.903
ALBO	0.902
SUMO	0.901
CMPI	0.901
NVCN	0.899
IMRX	0.885
NLTX	0.885

10 Correlaciones Más Negativas
MSBI	-0.949
BWFG	-0.948
NFBK	-0.946
CNOB	-0.944
ONB	-0.944
PFBC	-0.944
FBIZ	-0.943
PGC	-0.943
BCBP	-0.941
WSFS	-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Corbus Pharmaceuticals Correlación - Moneda/Commodity

-0.26
( neutral )

-0.24
( neutral )

0.62
( weak )

0.32
( neutral )

0.60
( weak )

0.46
( neutral )

Corbus Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.49M (0.00 %)
EPS:	$-13.39

FY	2021
Ingresos:	$881 705
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.